ProAlt’s MetasCure project selected in the R&D and innovation programme of Madrid Region
January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]